Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Endocrine 1Breast 1

Conditions

Breast Neoplasms 25Neoplasms 5Prostatic Neoplasms 4Neoplasm Metastasis 3Multiple Myeloma 2Thyroid Neoplasms 1Parathyroid Neoplasms 1Osteoporotic Fractures 1Osteoporosis 1Osteopetrosis, mild autosomal recessive form 1Osteopetrosis, Autosomal Recessive 7 1Neoplastic Cells, Circulating 1Musculoskeletal Pain 1Lymphoma, Non-Hodgkin 1Lymphoma 1Lung Neoplasms 1Kidney Neoplasms 1Inflammatory Breast Neoplasms 1Hypercalcemia 1Humoral Hypercalcemia Of Malignancy 1Hodgkin Disease 1Head and Neck Neoplasms 1Fractures, Bone 1Endocrine Gland Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Ductal, Breast 1Breast Diseases 1Bone Diseases, Metabolic 1Arthralgia 1

Interventions

Zoledronic Acid 3Risedronic Acid 3Letrozole 2Exercise Movement Techniques 1Denosumab 1Calcium 1Aromatase Inhibitors 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bone Diseases, Metabolic × Denosumab × Breast × Clear all
NCT00089661 2018-10-17

AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer

Amgen

Phase 3 Completed
252 enrolled 13 charts
Breast

Bone Diseases, Metabolic, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡